John M. Fevig

Discovery of 1-[3-(Aminomethyl)phenyl]-<i>N</i>-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1<i>H</i>-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Shuaige Wang et al. · Journal of Medicinal Chemistry · 2001 · 172 citations · Full text

Structure-Based Design of Novel Guanidine/Benzamidine Mimics:  Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants

Patrick Y. S. Lam, Charles G. Clark, Renhua Li et al. · Journal of Medicinal Chemistry · 2003 · 95 citations · Full text

Pharmaceutical Science, Oral Bioavailability, Pharmacotherapy +18

Synthesis applications of cationic aza-Cope rearrangements. 24. The aza-Cope-Mannich approach to Strychnos alkaloids. Short stereocontrolled total syntheses of (.+-.)-dehydrotubifoline and (.+-.)-akuammicine

Steven R. Angle, John M. Fevig, Steven D. Knight et al. · Journal of the American Chemical Society · 1993 · 86 citations

Cationic Aza-cope Rearrangements, Engineering, Biochemistry +12

New approach to Strychnos alkaloids. Stereocontrolled total synthesis of (.+-.)-dehydrotubifoline

John M. Fevig, Robert W. Marquis, Larry E. Overman · Journal of the American Chemical Society · 1991 · 70 citations

Bioorganic Chemistry, Engineering, Biochemistry +13

Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa

John M. Fevig, Joseph Cacciola, Joseph Buriak et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 53 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Biochemistry +11